[go: up one dir, main page]

WO2008016278A1 - Furan-2-carboxylic acid derivatives and process for the preparation thereof - Google Patents

Furan-2-carboxylic acid derivatives and process for the preparation thereof Download PDF

Info

Publication number
WO2008016278A1
WO2008016278A1 PCT/KR2007/003744 KR2007003744W WO2008016278A1 WO 2008016278 A1 WO2008016278 A1 WO 2008016278A1 KR 2007003744 W KR2007003744 W KR 2007003744W WO 2008016278 A1 WO2008016278 A1 WO 2008016278A1
Authority
WO
WIPO (PCT)
Prior art keywords
furan
compound
carboxylic acid
formula
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2007/003744
Other languages
French (fr)
Inventor
Hyae-Gyeong Cheon
Kwang-Rok Kim
Sang-Dal Rhee
Won-Hoon Jung
Hee-Youn Kim
Jong-Cheol Lee
Jung-Hwa Lee
Kyung Lee
Sung-Wuk Kim
Sung-Soo Jun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Chemical Technology KRICT
Hanall Pharmaceutical Co Ltd
Original Assignee
Korea Research Institute of Chemical Technology KRICT
Hanall Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Chemical Technology KRICT, Hanall Pharmaceutical Co Ltd filed Critical Korea Research Institute of Chemical Technology KRICT
Publication of WO2008016278A1 publication Critical patent/WO2008016278A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to a novel furan-2-carboxylic acid derivative capable of activating AMP-activated protein kinase (AMPK), which is useful for the prevention and treatment of metabolic syndromes.
  • AMPK AMP-activated protein kinase
  • Metabolic syndrome refers to a cluster of conditions including diabete (e.g., Type 2 diabete), obesity, hyperlipidemia, hypercholesterolemia, fatty liver and steatohepatitis factors, which raises patients' risk of being afflicted by coronary atherosclerosis, myocardial infarction and stroke 3 times or higher than normal people. The occurrence of metabolic syndromes has gradually increased.
  • AMPK is an energy sensor found in all eukaryotic cells, which is involved in metabolism regulation: it is activated in response to an increase in the ratio of AMP/ATP in cells due to cellular or body energy depletion and the phosphorylation of threonine 172 of AMPK.
  • AMPK regulates glucose absorption in muscle and fat cells. It is reported that AMPK is activated by the treatment of an AMPK activator, e.g., AICAR (5-aminoimidazol-4-carboxamide-l-D- ribofuranoside) in muscle cells to increase the translocation of a glucose transport protein GLUT 4 to the cell membrane, thereby raising glucose absorption in the cells ⁇ See Edward O. Ojuka et al., JAppl Physiol., 88(3), 1072-1075, 2000; and Honghai Zheng, J Appl Physiol., 91, 1073-1083, 2001).
  • AICAR 5-aminoimidazol-4-carboxamide-l-D- ribofuranoside
  • AMPK reduces fat synthesis through lowering the expression of a sterol regulatory element binding protein- Ic (SREBP-Ic) which controls the synthesis of acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), and it also inhibits the activity of ACC by directly phosphorylating ACC.
  • SREBP-Ic sterol regulatory element binding protein- Ic
  • ACC acetyl-CoA carboxylase
  • FAS fatty acid synthase
  • the activated AMPK reduces the formation of fat such as triglyceride or cholesterol in cells (See Trends in Pharmacological Science, 26, 69-76, 2005), which is beneficial in regulating much conditions as obesity and glucose metabolic disturbance of metabolic syndromes (See Neil et al., Nature Drug discovery, 3, 340, 2004).
  • metformin As an AMPK-activating drug, metformin has been used for treating Type 2 diabete (See Current drug targets, 4, 685-696, 2005), but, it causes gastric-related side effects such as diarrhea.
  • X is hydrogen or halogen
  • R is hydrogen or C 1-4 alkyl; n is an integer in the range of 1 to 3; and m is an integer in the range of 0 to 2.
  • the present invention also provides a method for preparing the compound of formula (I), comprising bringing a compound of formula (II) to react with a compound of formula (III) in a solvent in the presence of a base:
  • Y is triphenylphosphonium bromide, triphenylphosphonium iodide or benzothiazol-2-sulfonyl
  • the present invention further provides a pharmaceutical composition for preventing or treating metabolic syndromes, comprising the compound of formula (I), a pharmaceutically acceptable salt or isomer thereof as an active ingredient.
  • FIG. 1 shows Western blot analyze results obtained for the activation of AMPK by the inventive furan-2-carboxylic acid derivative.
  • the present invention provides a novel compound of formula (I), a pharmaceutically acceptable salt or isomer thereof as an AMPK activator.
  • the pharmaceutically acceptable salt of the inventive compound of formula (I) includes a salt formed with an inorganic base such as an alkali metal (e.g., lithium, sodium and potassium), an alkaline earth metal (e.g., calcium and magnesium) or chromium, or an organic base such as amines (e.g., quaternary ammonium, dicyclohexyl amine and N-methyl-D-glucamine) or amino acids (e.g., arginine and lycine).
  • an inorganic base such as an alkali metal (e.g., lithium, sodium and potassium), an alkaline earth metal (e.g., calcium and magnesium) or chromium, or an organic base such as amines (e.g., quaternary ammonium, dicyclohexyl amine and N-methyl-D-glucamine) or amino acids (e.g., arginine and lycine).
  • inventive compound of formula (I) may exist in an E- or Z- isomer due to the existence of a double-bond therein. Accordingly, the present invention includes an E- or Z-isomer of the compound of formula (I) and a racemic mixture thereof.
  • Exemplary compounds of formula (I) according to the present invention are as follows:
  • the inventive compound of formula (I) can be prepared by bringing a compound of formula (II) to react with a compound of formula (III) in a solvent in the presence of a base, as shown in Reaction Scheme 1.
  • Reaction Scheme 1 Reaction Scheme 1
  • Y is triphenylphosphonium bromide, triphenylphosphonium iodide or benzothiazol-2-sulfonyl; and X, R, n and m are the same as defined in formula (I).
  • the compound of formula (Ia) containing one double bond may be prepared by conducting a conventional olefination reaction such as Wittig reaction and Julia olefination.
  • the compound of formula (II) and the compound of formula (III) are preferably used in an equivalent ratio of 1.0:0.8 to 1.0:1.5 in a solvent in the presence of a base.
  • Examples of the base which may be used in the Wittig reaction include, but are not limited to, potassium £-butoxide, sodium ⁇ -butoxide, sodium methoxide, sodium ethoxide, sodium hydride, n-butyl lithium, r-butyl lithium and a mixture thereof, preferably potassium ⁇ -butoxide.
  • the base is suitably used in 1.0 to 3.0 equivalents based on the compound of formula (II).
  • Examples of the base which may be used in the Julia olefination reaction include, but are not limited to, sodium (bis-trimethylsilyl)amide, lithium (bis-trimethylsilyl)amide, potassium (bis-trimethylsilyl)amide, potassium ⁇ -butoxide, sodium ⁇ -butoxide, sodium methoxide, sodium ethoxide and a mixture thereof, preferably lithium (bis-trimethylsilyl)amide.
  • the base is suitably used in 1.0 to 3.0 equivalents based on the compound of formula (II).
  • the solvent which may be used in the Wittig or Julia olefination reaction is dimethyl formamide (DMF), tetrahydrofuran (THF), diethyl ether (Et 2 U), dimethoxyethane (DME) or a mixture thereof, preferably dimethyl formamide.
  • the solvent is suitably used in an amount of 1.0 to 4.0 m£, preferably 2.5 to 3.0 mi based on 1 mmol of the reactant, and the reaction is preferably conducted at a temperature ranging from -78 0 C to the boiling point of the solvent used.
  • the compound of formula (Ia) thus prepared is a racemic mixture, whose isomer mix ratio can be confirmed by an H-NMR analysis, and if necessary, each isomer may be isolated therefrom according to a conventional separation method such as chromatography. Further, the compound of formula (Ia) may be subjected to hydrogenation using a palladium/charcoal catalyst to obtain the compound of formula (Ib).
  • Reaction Scheme 1 is preferably 5-formyl-furan-2-carboxylic acid or methyl 5-formyl-furan-2-carboxylate.
  • the former is commercially available and the latter can be easily obtained from methylation of 5-formyl-furan-2-carboxylic acid.
  • the compound of formula (II) used as another starting material in Reaction Scheme 1 may be prepared as shown in Reaction Scheme 2.
  • X, R 3 n and m are the same as defined in formula (I)
  • Y is the same as defined in Reaction Scheme 1
  • L is hydroxyl group or a conventional leaving group such as halogen, alkylsulfonyl and arylsulfonyl.
  • the compound of formula (IV) is commercially available or may be easily prepared by substituting a hydroxyl group-containing compound with a conventional leaving group in accordance with a conventional method.
  • the compound of formula (V) is also commercially available or may be easily prepared by reducing an aldehyde or carboxylic acid group-containing compound in accordance with a conventional method.
  • the compound of formula (IV) and the compound of formula (V) are preferable used in a molar ratio ranging from 1.0:1.0 to 1.5:1.0 in a solvent in the presence of a base for the alkylation or Mitsunobu reaction of phenoxy group, to obtain the compound of formula (VI).
  • the solvent useful in said reaction is DMF, acetone or acetonitrile.
  • the base useful in said reaction is potassium carbonate or cesium carbonate.
  • the compound of formula (VI) may be subjected to a substitution reaction with triphenylphosphonium bromide, triphenylphosphonium iodide or benzothiazol-2-sulfonyl, to obtain the compound of formula (II).
  • the compound of formula (II) wherein Y is triphenylphosphonium bromide or triphenylphosphonium iodide may be prepared by dissolving the compound of formula (VI) in dichloromethane or diethyl ether, adding 30% hydrogen bromide/acetic acid solution or N-iodosuccinimide thereto, mixing the resulting bromide or iodide compound with triphenylphosphine in dimethyl formamide and stirring the mixture at room temperature for 1 to 3 hours.
  • the 30% hydrogen bromide/acetic acid solution is used in an amount of 1 to 10 equivalents (HBr base) relative to the compound of formula (VI); the N-iodosuccinimide, 1 to 5 equivalents; and triphenylphosphine, 1 to 3 equivalents.
  • the compound of formula (II) wherein Y is benzothiazol-2-sulfonyl may be prepared by mixing the compound of formula (VI) withbenzo[di]thiazol-2-thiol (1 to 3 equivalents), triphenylphosphine (1 to 3 equivalents) and diethyl azodicarboxylate (DEAD) (1 to 3 equivalents) in a solvent such as THF or DMF, followed by stirring at room temperature for 1 to 3 hours to substitute the hydroxyl group of the compound of formula (VI) with benzo[di]thiazol-2-thiol, and oxidizing the resultant using m-chloroperbenzoic acid (3 to 5 equivalents) and sodium bicarbonate (5 to 10 equivalents).
  • the oxidation is suitably conducted at a temperature ranging from room temperature to the boiling point of the solvent used for 2 to 4 hours.
  • the present invention provides a pharmaceutical composition for preventing or treating metabolic syndromes, comprising the inventive compound of formula (I), a pharmaceutically acceptable salt or isomer thereof as an active ingredient.
  • composition of the present invention may be formulated in a form suitable for a desired use or purpose using conventional pharmaceutically acceptable additives such as excipient, filler, binder, lubricant, disintegrant, coating agent, emulsifier, suspending agent, solvent, stabilizing agent, penetration enhancer, and ointment.
  • conventional pharmaceutically acceptable additives such as excipient, filler, binder, lubricant, disintegrant, coating agent, emulsifier, suspending agent, solvent, stabilizing agent, penetration enhancer, and ointment.
  • the pharmaceutical composition may be orally administered in the form of tablets, coated tablets, capsules, powders, granules, solutions, emulsions or suspensions. Also, the pharmaceutical composition may be rectally administered in the form of suppositorys, topically or transdermally in the form of ointments, creams, gels or solutions, or parenterally in the form of an injection solutions.
  • the amount of the inventive compound of formula (I) actually administered will be determined depending on various factors including the age and condition of the patient and the chosen route of administration.
  • the suitable daily dosage for oral administration of the compound of formula (I) is about 100 to 500 mg for an adult patient.
  • Step (1-4) The compound (0.17 mmol) obtained in Step (1-4) was dissolved in a 1:9 (v/v) mixture of methanol and dichloromethane, and 5% palladium/charcoal (Pd/C) catalyst was added thereto. The resulting mixture was saturated with hydrogen (hydrogen gas balloon), stirred for 3 hours, filtered, and concentrated under a reduced pressure. The residue was purified by silica gel column chromatography (2% dichloromethane/methanol), to obtain the title compound (Yield 80%).
  • Step (2-4) The compound (0.164 mmol) obtained in Step (2-4) was dissolved in water/THF (1/1, 2 mi), and lithium hydroxide (LiOH) (0.49 mmol) was added thereto, followed by stirring for 12 hours.
  • the mixture was neutralized with IN hydrochloric acid and extracted with water and ethyl acetate (1:1, 2 mi).
  • the organic layer was washed with brine, dried over anhydrous Mg 2 SO 4 , filtered and concentrated.
  • Example 3 5- ⁇ 3-[3-(4-fluorobenzyloxy)phenyl]propyl ⁇ furan-2- carboxylic acid (E)/(Z)-5- ⁇ 3-[3-(4-fluorobenzyloxy)phenyl]propenyl ⁇ furan-2-carboxy lie acid (0.16 mmol) obtained in Example 2 was hydrogenated according to the procedure of Step (1-5) of Example 1, to obtain the title compound (Yield 59%).
  • Example 1 and 3-hydroxyphenyl acetic acid were used as starting materials for conducting the procedures of Step (1-2) of Example I 5 Step (2-3) (Yield 62%) and Step (2-4) (Yield 36%) of Example 2, Step (1-5) of Example 1 and Step (2-5) (Yield 62%) of Example 2, successively, to obtain the title compound.
  • Step (2-2) of Example 2 was repeated except for using 3-hydroxybenzyl alcohol as a starting material, to obtain the title compound.
  • Step (1-4) of Example 1 was repeated except for using the compound (0.28 mmol) obtained in Step (5-2), to obtain the title compound (Yield 52%).
  • Step (1-5) of Example 1 was repeated except for using the compound (0.12 mmol) obtained in Step (5-3), to obtain the title compound (Yield 50%).
  • Step (1-1) of Example 1 2-Hydroxybenzyl alcohol and 2-(4-fluorophenyl)-ethyl methanesulfonate obtained in Step (1-1) of Example 1 were used as starting materials for conducting the procedures of Step (1-2), Step (1-3) (Yield 89%), Step (1-4) (Yield 50%) and Step (1-5) (Yield 90%) of Example 1, successively, to obtain the title compound.
  • Step (1-1) of Example 1 2-Hydroxybenzyl alcohol and 2-(4-fluorophenyl)-ethyl methane sulfonate obtained in Step (1-1) of Example 1 were used as starting materials for conducting the procedures of Step (1-2), Step (1-3) (Yield 89%) and Step (1-4) (Yield 50%) of Example 1, successively, to obtain the title compound.
  • Hepatoma HepG2 cells obtained from the Korean Cell Line Bank were cultured in DMEM (Dulbecco's Modified Eagle Medium) at a concentration of IxIO 4 cells /well.
  • the cells were treated with each of the test compounds of the present invention (100 ⁇ M), metformin (2 mM) (Sigma) and AICAR (100 ⁇ M) (Sigma) as comparative compounds, and the control group without test compound, which were incubated in a humidified atmosphere of 5% CO 2 at 37 ° C for 24 hours. Then, the cells were treated with a Pro-Prep protein extract solution (ESTtRON Biotechnology).
  • the extracted protein was separated in SDS-PAGE and electrophoretically transferred to protein-fixing membranes, followed by incubation with the anti-AMPK antibody (Cell signaling) or anti-phospho-AMPK (pAMPK) antibody (Cell signaling).
  • a light-sensitive film was used to detect immunoreactive bands and the intensity of bands was quantified.
  • the AMPK activity increase brought about by the test compound treatment was measured by dividing the intensity of pAMPK with the intensity of AMPK.
  • Table 1 The results are shown in Table 1, in the form of the extent of increase of the AMPK activity relative to AICAR (The measurement for AICAR is assigned to "1").
  • Hepatoma HepG2 cells obtained from the Korean Cell Line Bank were cultured in DMEM at a concentration of IxIO 4 cells /well.
  • the cells were treated with each of the test compounds of the present invention (50 ⁇ M), and the control group without test compound, which were incubated in an atmosphere of 5% CO 2 at 37 °C for 24 hours.
  • the cells were treated with a cell lysis solution (0.1 M potassium phosphate, pH 7.4, 0.05 M NaCl, 5 inM cholic acid, 0.1% Triton ® X-100) and reacted on ice for 10 minutes.
  • the cell lysates were treated with 50 j ⁇ of a 2 times-concentrated reagent (300 ⁇ M Amplex Red reagent (Invitorgen), 2 O/ml HRP (Invitorgen), 2 U/m- ⁇ cholesterol oxidase (Invitorgen), 0.2 Wmt cholesterol esterase (Invitorgen)) and reacted for 30 minutes at 37 ° C .
  • the content of cholesterol formed in the cell lysates was measured using a fluorscence microscope and .quantified. The results are shown in Table 2, in the form of the cholesterol content (%) relative to the control group (The measurement for control group is assigned to "100%").
  • Table 2 Table 2
  • Hepatoma HepG2 cells obtained from the Korean Cell Line Bank were cultured in DMEM at a concentration of 2 ⁇ l O 4 cells /well.
  • the cells were treated with each of the test compounds of the present invention (50 ⁇ M), and the control group without test compound, which were incubated in an atmosphere of 5% CO 2 at 37 ° C for 24 hours.
  • the cells were treated with a cell lysis solution (0.1 M potassium phosphate, pH 7.4, 0.05 M NaCl, 5 mM cholic acid, 0.1% Triton ® X-100) and reacted on ice for 10 minutes.
  • a cell lysis solution 0.1 M potassium phosphate, pH 7.4, 0.05 M NaCl, 5 mM cholic acid, 0.1% Triton ® X-100
  • the cell lysates were treated with 50 ⁇ JL of a 2 times-concentrated reagent (300 ⁇ M Amplex Red reagent (Invitorgen), 2 UM lipase (ASAN Pharmaceutical Co., Ltd.), 0.75 UM glycerol kinase (ASAN Pharmaceutical Co., Ltd.), 151333 UM peroxidase (ASAN Pharmaceutical Co., Ltd.), 22.2 UM glyceric oxidase (ASAN Pharmaceutical Co., Ltd.) and reacted for 30 minutes at 37 0 C .
  • the content of the triglyceride formed in the cell lysates was measured using a fluorscence microscope and quantified. The results are shown in Table 3, in the form of the triglyceride content (%) relative to the control group (The measurement for control group is assigned to "100%")- Table 3
  • Hepatoma HepG2 cells were cultured in DMEM at a concentration of 5 ⁇ l O 4 cells /well. The cells were treated with each of the test compounds of the present invention (50 ⁇ M), and the control group without test compound, which were incubated in an atmosphere of 5% CO 2 at 37 0 C for 24 hours. Then, 0.5 uCi 14C-lactate (Amersham Bioscience) and 10 mM L-lactate
  • the inventive compound is effective in the activation of AMPK, which is useful for preventing or treating metabolic syndromes including diabete (e.g., Type 2 diabete), obesity, hyperlipidemia, hypercholesterolemia, fatty liver and steatohepatitis factors.
  • diabete e.g., Type 2 diabete
  • obesity e.g., obesity
  • hyperlipidemia e.g., hypercholesterolemia
  • fatty liver e.g., steatohepatitis factors.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to a furan-2-carboxylic acid derivative capable of activating AMP-activated protein kinase (AMPK), which is useful for the prevention and treatment of metabolic syndromes including diabete, obesity, hyperlipidemia, hypercholesterolemia, fatty liver and steatohepatitis factors.

Description

FURAN-l-CARBOXYLIC ACID DERIVATIVES AND PROCESS FOR
THE PREPARATION THEREOF
Field of the Invention
The present invention relates to a novel furan-2-carboxylic acid derivative capable of activating AMP-activated protein kinase (AMPK), which is useful for the prevention and treatment of metabolic syndromes.
Background of the Invention
Metabolic syndrome refers to a cluster of conditions including diabete (e.g., Type 2 diabete), obesity, hyperlipidemia, hypercholesterolemia, fatty liver and steatohepatitis factors, which raises patients' risk of being afflicted by coronary atherosclerosis, myocardial infarction and stroke 3 times or higher than normal people. The occurrence of metabolic syndromes has gradually increased.
Metabolic syndromes are associated with AMPK, a metabolic regulator. AMPK is an energy sensor found in all eukaryotic cells, which is involved in metabolism regulation: it is activated in response to an increase in the ratio of AMP/ATP in cells due to cellular or body energy depletion and the phosphorylation of threonine 172 of AMPK.
The activated AMPK regulates glucose absorption in muscle and fat cells. It is reported that AMPK is activated by the treatment of an AMPK activator, e.g., AICAR (5-aminoimidazol-4-carboxamide-l-D- ribofuranoside) in muscle cells to increase the translocation of a glucose transport protein GLUT 4 to the cell membrane, thereby raising glucose absorption in the cells {See Edward O. Ojuka et al., JAppl Physiol., 88(3), 1072-1075, 2000; and Honghai Zheng, J Appl Physiol., 91, 1073-1083, 2001).
AMPK reduces fat synthesis through lowering the expression of a sterol regulatory element binding protein- Ic (SREBP-Ic) which controls the synthesis of acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), and it also inhibits the activity of ACC by directly phosphorylating ACC. Thus, the activated AMPK reduces the formation of fat such as triglyceride or cholesterol in cells (See Trends in Pharmacological Science, 26, 69-76, 2005), which is beneficial in regulating much conditions as obesity and glucose metabolic disturbance of metabolic syndromes (See Neil et al., Nature Drug discovery, 3, 340, 2004).
As an AMPK-activating drug, metformin has been used for treating Type 2 diabete (See Current drug targets, 4, 685-696, 2005), but, it causes gastric-related side effects such as diarrhea.
Summary of the Invention
Accordingly, it is a primary object of the present invention to provide a novel compound, which is capable of activating AMPK to inhibit the formation of fatty acid and glucose and facilitate glucose absorption in cells, with no side effects.
It is another object of the present application to provide a method for preparing said compound.
It is a further object of the present application to provide a pharmaceutical composition comprising said compound as an active ingredient, for preventing or treating metabolic syndromes such as insulin-independent diabetes mellitus, obesity and atherosclerosis.
In accordance with one aspect of the present invention, there is provided a furan-2-carboxylic acid derivative of formula (I) or a pharmaceutically acceptable salt or isomer thereof:
Figure imgf000004_0001
wherein,
X is hydrogen or halogen;
R is hydrogen or C1-4 alkyl; n is an integer in the range of 1 to 3; and m is an integer in the range of 0 to 2.
The present invention also provides a method for preparing the compound of formula (I), comprising bringing a compound of formula (II) to react with a compound of formula (III) in a solvent in the presence of a base:
Figure imgf000005_0001
wherein, Y is triphenylphosphonium bromide, triphenylphosphonium iodide or benzothiazol-2-sulfonyl; and
X, R, n and m are the same as defined in formula (I).
The present invention further provides a pharmaceutical composition for preventing or treating metabolic syndromes, comprising the compound of formula (I), a pharmaceutically acceptable salt or isomer thereof as an active ingredient.
Brief Description of the Drawings
The above and other objects and features of the present invention will become apparent from the following description of the invention taken in conjunction with the accompanying FIG. 1 which shows Western blot analyze results obtained for the activation of AMPK by the inventive furan-2-carboxylic acid derivative.
Detailed Description of the Invention The present invention provides a novel compound of formula (I), a pharmaceutically acceptable salt or isomer thereof as an AMPK activator.
Among the compounds of formula (I) of the present invention, preferred are those wherein R is hydrogen or methyl. The pharmaceutically acceptable salt of the inventive compound of formula (I) includes a salt formed with an inorganic base such as an alkali metal (e.g., lithium, sodium and potassium), an alkaline earth metal (e.g., calcium and magnesium) or chromium, or an organic base such as amines (e.g., quaternary ammonium, dicyclohexyl amine and N-methyl-D-glucamine) or amino acids (e.g., arginine and lycine).
Also, the inventive compound of formula (I) may exist in an E- or Z- isomer due to the existence of a double-bond therein. Accordingly, the present invention includes an E- or Z-isomer of the compound of formula (I) and a racemic mixture thereof. Exemplary compounds of formula (I) according to the present invention are as follows:
1) 5-(2- {3-[2-(4-fluorophenyl)ethoxy]phenyl}ethyl)furan-2-carboxylic acid;
2) (E)/(Z)-5- {3-[3-(4-fluorobenzyloxy)phenyl]propenyl}furan-2- carboxylic acid; 3) 5-{3-[3-(4-fluorobenzyloxy)phenyl]propyl}furan-2-carboxylic acid;
4) 5-(3-{3-[2-(4-fluorophenyl)ethoxy]phenyl}propyl)furan-2-carboxylic acid;
5) 5- {2-[3-(4-fluorobenzyloxy)phenyl]ethyl}furan-2-carboxylic acid;
6) 5-{2-[2-(4-fluorobenzyloxy)phenyl]ethyl}furan-2-carboxylic acid; 7) 5-(2-{2-[2-(4-fluorophenyl)ethoxy]phenyl}ethyl)furan-2-carboxylic acid;
8) (E)/(Z)-5-(2-{2-[2-(4-fluoroρhenyl)ethoxy]phenyl}vinyl)furan-2- carboxylic acid; and
9) (E)/(Z)-5- {2- [2-(4-fluorobenzyloxy)phenyl] vinyl} furan-2-carboxylic acid.
The inventive compound of formula (I) can be prepared by bringing a compound of formula (II) to react with a compound of formula (III) in a solvent in the presence of a base, as shown in Reaction Scheme 1. Reaction Scheme 1
Figure imgf000007_0001
Pd /H
Figure imgf000007_0002
Ib wherein, Y is triphenylphosphonium bromide, triphenylphosphonium iodide or benzothiazol-2-sulfonyl; and X, R, n and m are the same as defined in formula (I).
In Reaction Scheme 1, the compound of formula (Ia) containing one double bond may be prepared by conducting a conventional olefination reaction such as Wittig reaction and Julia olefination.
For the Wittig reaction, the compound of formula (II) and the compound of formula (III) are preferably used in an equivalent ratio of 1.0:0.8 to 1.0:1.5 in a solvent in the presence of a base.
Examples of the base which may be used in the Wittig reaction include, but are not limited to, potassium £-butoxide, sodium ^-butoxide, sodium methoxide, sodium ethoxide, sodium hydride, n-butyl lithium, r-butyl lithium and a mixture thereof, preferably potassium ^-butoxide. The base is suitably used in 1.0 to 3.0 equivalents based on the compound of formula (II).
For the Julia olefination, it is preferred that the compound of formula (II) wherein Y is benzothiazol-2-sulfonyl is allowed to react with the compound of formula (IJJ) in an equivalent ratio of 1.0:0.8 to 1.0:1.5 in a solvent in the presence of a base.
Examples of the base which may be used in the Julia olefination reaction include, but are not limited to, sodium (bis-trimethylsilyl)amide, lithium (bis-trimethylsilyl)amide, potassium (bis-trimethylsilyl)amide, potassium ^-butoxide, sodium ^-butoxide, sodium methoxide, sodium ethoxide and a mixture thereof, preferably lithium (bis-trimethylsilyl)amide. The base is suitably used in 1.0 to 3.0 equivalents based on the compound of formula (II).
The solvent which may be used in the Wittig or Julia olefination reaction is dimethyl formamide (DMF), tetrahydrofuran (THF), diethyl ether (Et2U), dimethoxyethane (DME) or a mixture thereof, preferably dimethyl formamide.
The solvent is suitably used in an amount of 1.0 to 4.0 m£, preferably 2.5 to 3.0 mi based on 1 mmol of the reactant, and the reaction is preferably conducted at a temperature ranging from -780C to the boiling point of the solvent used.
The compound of formula (Ia) thus prepared is a racemic mixture, whose isomer mix ratio can be confirmed by an H-NMR analysis, and if necessary, each isomer may be isolated therefrom according to a conventional separation method such as chromatography. Further, the compound of formula (Ia) may be subjected to hydrogenation using a palladium/charcoal catalyst to obtain the compound of formula (Ib).
The furan carbaldehyde of formula (III) used as a starting material in
Reaction Scheme 1 is preferably 5-formyl-furan-2-carboxylic acid or methyl 5-formyl-furan-2-carboxylate. The former is commercially available and the latter can be easily obtained from methylation of 5-formyl-furan-2-carboxylic acid.
The compound of formula (II) used as another starting material in Reaction Scheme 1 may be prepared as shown in Reaction Scheme 2.
Reaction Scheme 2
Figure imgf000008_0001
w wherein, X, R3 n and m are the same as defined in formula (I), Y is the same as defined in Reaction Scheme 1, and L is hydroxyl group or a conventional leaving group such as halogen, alkylsulfonyl and arylsulfonyl.
In Reaction Scheme 2, the compound of formula (IV) is commercially available or may be easily prepared by substituting a hydroxyl group-containing compound with a conventional leaving group in accordance with a conventional method. The compound of formula (V) is also commercially available or may be easily prepared by reducing an aldehyde or carboxylic acid group-containing compound in accordance with a conventional method. The compound of formula (IV) and the compound of formula (V) are preferable used in a molar ratio ranging from 1.0:1.0 to 1.5:1.0 in a solvent in the presence of a base for the alkylation or Mitsunobu reaction of phenoxy group, to obtain the compound of formula (VI). The solvent useful in said reaction is DMF, acetone or acetonitrile. The base useful in said reaction is potassium carbonate or cesium carbonate.
The compound of formula (VI) may be subjected to a substitution reaction with triphenylphosphonium bromide, triphenylphosphonium iodide or benzothiazol-2-sulfonyl, to obtain the compound of formula (II). The compound of formula (II) wherein Y is triphenylphosphonium bromide or triphenylphosphonium iodide may be prepared by dissolving the compound of formula (VI) in dichloromethane or diethyl ether, adding 30% hydrogen bromide/acetic acid solution or N-iodosuccinimide thereto, mixing the resulting bromide or iodide compound with triphenylphosphine in dimethyl formamide and stirring the mixture at room temperature for 1 to 3 hours. The 30% hydrogen bromide/acetic acid solution is used in an amount of 1 to 10 equivalents (HBr base) relative to the compound of formula (VI); the N-iodosuccinimide, 1 to 5 equivalents; and triphenylphosphine, 1 to 3 equivalents. Also, the compound of formula (II) wherein Y is benzothiazol-2-sulfonyl may be prepared by mixing the compound of formula (VI) withbenzo[di]thiazol-2-thiol (1 to 3 equivalents), triphenylphosphine (1 to 3 equivalents) and diethyl azodicarboxylate (DEAD) (1 to 3 equivalents) in a solvent such as THF or DMF, followed by stirring at room temperature for 1 to 3 hours to substitute the hydroxyl group of the compound of formula (VI) with benzo[di]thiazol-2-thiol, and oxidizing the resultant using m-chloroperbenzoic acid (3 to 5 equivalents) and sodium bicarbonate (5 to 10 equivalents). The oxidation is suitably conducted at a temperature ranging from room temperature to the boiling point of the solvent used for 2 to 4 hours.
Furthermore, the present invention provides a pharmaceutical composition for preventing or treating metabolic syndromes, comprising the inventive compound of formula (I), a pharmaceutically acceptable salt or isomer thereof as an active ingredient.
The pharmaceutical composition of the present invention may be formulated in a form suitable for a desired use or purpose using conventional pharmaceutically acceptable additives such as excipient, filler, binder, lubricant, disintegrant, coating agent, emulsifier, suspending agent, solvent, stabilizing agent, penetration enhancer, and ointment.
The pharmaceutical composition may be orally administered in the form of tablets, coated tablets, capsules, powders, granules, solutions, emulsions or suspensions. Also, the pharmaceutical composition may be rectally administered in the form of suppositorys, topically or transdermally in the form of ointments, creams, gels or solutions, or parenterally in the form of an injection solutions.
The amount of the inventive compound of formula (I) actually administered will be determined depending on various factors including the age and condition of the patient and the chosen route of administration. The suitable daily dosage for oral administration of the compound of formula (I) is about 100 to 500 mg for an adult patient.
The present invention will be described in further detail with reference to Examples. However, it should be understood that the present is not restricted by the specific Examples.
Example 1: Preparation of 5-(2-{3-[2-(4-fluorophenyl)ethoxy]phenyl} ethyl)furan-2-carboxylic acid
(1-1) Preparation of 2-(4-fluorophenyl)-ethyl methanesulfonate
2-(4-Fluorophenyl)~ethanol (7.13 mmol) was dissolved in dichloromethane (10 m£), to which methanesulfonyl chloride (7.84 mmol) and triethylamine (10.7 mmol) were added. The mixture was slowly to react at room temperature for 1 hour, the reaction mixture was washed with IN hydrochloric acid, and water was added thereto. The resultant was extracted with dichloromethane and washed with brine. The organic layer was dried over Na2SO4 and concentrated under a reduced pressure, to obtain the title compound.
(1-2) Preparation of (3-r2-(4-fluorophenyl)-emoxylphenyl)methanol
The compound (1.76 mmol) obtained in Step (1-1) and 3-hydroxyben2yl alcohol (1.94 mmol) were dissolved in acetonitrile (10 ml), to which potassium carbonate (K2CO3) (3.62 mmol) was added. The mixture was refluxed for 12 hours, filtered, and concentrated under a reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate = 3:1), to obtain the title compound (Yield 80%).
(1-3) Preparation of {3-[2-(4-fluorophenyl)-emoxy1phenyl|bromomethane
The compound (1.22 mmol) obtained in Step (1-2) was dissolved in 2 m£ of a 9:1 (v/v) mixture of hydrogen bromide (30% in AcOH) and dichloromethane, stirred at room temperature for 2 hours, and concentrated under a reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate = 3:1), to obtain the title compound (Yield 59%).
d-4) Preparation of (E)/(Z)-5(2-{3-r2-(4-fluorophenyl)-emoxy1ρhenvU vmyl)furan-2-carboxylic acid
The compound (1.30 mmol) obtained in Step (1-3) was dissolved in a solution of triphenyl phosphine (1.46 mmol) in DMF (10 id) and the resulting solution was vigorously stirred at room temperature for 2 hours. 5-Formyl-furan-2-carboxylic acid (0.76 mmol) and potassium /-butoxide (5.49 mmol) was added thereto and stirred at room temperature for 5 hours. 10% hydrochloric acid solution was added to the resultant, followed by extracting with ethyl acetate. The organic layer was dried over Na2SO4 and concentrated under a reduced pressure. The residue was purified by silica gel column chromatography (2% dichloromethane/methanol), to obtain the title compound (Yield 45%).
(1-5) Preparation of 5(2-{3-f2-('4-fluorophenylVethoxylphenyllethvπfuran- 2-carboxylic acid
The compound (0.17 mmol) obtained in Step (1-4) was dissolved in a 1:9 (v/v) mixture of methanol and dichloromethane, and 5% palladium/charcoal (Pd/C) catalyst was added thereto. The resulting mixture was saturated with hydrogen (hydrogen gas balloon), stirred for 3 hours, filtered, and concentrated under a reduced pressure. The residue was purified by silica gel column chromatography (2% dichloromethane/methanol), to obtain the title compound (Yield 80%).
1H-NMR (300MHz5 CDCl3) d 2.94 (m, 4H, CH2CH2), 3.05 (t, /= 6.9 Hz, 2H, CH2CH2O), 4.14 (t, J= 6.9 Hz, 2H, CH2CH2O), 6.12 (d, J= 3.3 Hz, IH, fur), 6.75 (m, 4H, Ph), 7.00 (m, 2H, Ph), 7.21 (m, 3H, Ph).
Example 2: Preparation of (E)/(Z)-5-{3-[3-(4-fluorobenzyloxy)phenyl] propenyl}furan-2-carboxylic acid
(2-1) Preparation of 3-(2-hvdroxyethyl)phenol
Boron trifluoride-diethyletherate (BF3Et2O) (4.27 mmol) was slowly added dropwise in a mixture of sodium borohydride (9.87 mmol) and 3-hydroxyphenyl acetic acid (6.58 mmol) dissolved in tetrahydrofuran (20 mJl). The mixture was refluxed for 3 hours, and water was added thereto. The resultant was extracted with ethyl acetate, dried over anhydrous Mg2Sθ4, filtered, and concentrated under a reduced pressure. The residue was purified by silica gel column chromatography, to obtain the title compound (Yield 85%).
(2-2) Preparation of 2-[3-(4-fluorobenzyloxy)phenyl'lethanol 3-(2-Hydroxyethyl)phenol (8.06 mmol) obtained in Step (2-1) and potassium carbonate (8.70 mmol) were dissolved in DMF, and l-(bromomethyl)-4-fluorobenzene (8.06 mmol) was added thereto, followed by stirring at room temperature for 12 hours. Water was added to the resultant, which was extracted with ethyl acetate, dried over anhydrous Mg2Sθ4, filtered, and concentrated under a reduced pressure. The residue was purified by silica gel column chromatography, to obtain the title compound (Yield 85%).
(2-3) Preparation of 2-[3-(4-fluorobenzyloxy)phenethylsulfonyl] benzo[d]thiazol
The compound (800 mg, 3.07 mmol) obtained in Step (2-2), benzo[di]thiazol-2-thiol (771 mg, 4.61 mmol) and triphenylphosphine (1.45mg, 553 mmol) were dissolved in THF (8 ml), to which diethylazodicarboxylic acid (DEAD) (0.68 ml, 4.61 mmol) was added. The mixture was stirred at room temperature for 1 hour, and water (26 ml) was added thereto. The resultant was extracted with ethyl acetate (80 ml X 2), washed with brine, dried over anhydrous Mg2Sθ4, filtered, and concentrated under a reduced pressure. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 20:1), to obtain 2-[3-(4-fluorobenzyloxy)phenethylthio]benzo[d]thiazol.
2-[3-(4-fluorobenzyloxy)phenethylthio]benzo[d]thiazol (1.7g, 4.15 mmol) obtained above, sodium bicarbonate (1.55g, 18.4 mmol) and m-chloroperoxybenzoic acid were dissolved in dichloromethane (20 ml), followed by stirring at room temperature for 4 hours. Sodium thiosulfite (Na2S2C^) was added to the solution, which was extracted with ethyl acetate (170 ml X 2). The extract was washed with brine, dried over anhydrous Mg2SO4, filtered, and concentrated under a reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate = 10:1), to obtain 1.1 g of the title compound (Yield 85%).
(2-4) Preparation of methyl (EVfZV5-(3-r3-f4-fluorobenzyloxy)pheαyl1 propenyl} furan-2-carboxylate
The compound (1.03 mmol) obtained in Step (2-3) and methyl 5-formylfuran-2-carboxylic acid (0.97 mmol) were dissolved in DMF (10 mi), to which lithium (bis-trimethylsilyl)amide (LiN(TMS)2) (1.24 mmol) was slowly added dropwise at -78 "C . The mixture was warmed to room temperature and stirred for 2 hours. A saturated aqueous solution (3 ml) of ammonium chloride (NH4CI) was added thereto, and the resultant was extracted with water and ethyl acetate (2/1, 30 mi). The organic layer was washed with brine, dried over anhydrous Mg2S O4-, filtered, and concentrated under a reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate = 20:1), to obtain 170 mg of the title compound (Yield 48 %).
(2-5) Preparation of (Ey(Zy5-J3-r3-(4-fluorobenzΛdoxy)phenyl]propenyl) furan-2-carboxylic acid
The compound (0.164 mmol) obtained in Step (2-4) was dissolved in water/THF (1/1, 2 mi), and lithium hydroxide (LiOH) (0.49 mmol) was added thereto, followed by stirring for 12 hours. The mixture was neutralized with IN hydrochloric acid and extracted with water and ethyl acetate (1:1, 2 mi). The organic layer was washed with brine, dried over anhydrous Mg2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography (hexane:ethyl acetate = 20:1), to obtain 50 mg of the title compound (Yield 87%).
1H-NMR (300MHz, CDCl3) d (E) 3.63 (d, J = 8.4 Hz, 2H, allylic), 5.01 (s, 2H, CH2), 6.26 (d, J= 15.9 Hz, IH, CH), 6.31 (d, /= 3.5 Hz, IH5 fur), 6.62 (d, J= 15.9 Hz, IH, CH), 7.03-7.42 (m, 9H, Ph, fur); MS m/z 352 (M+, 0.3), 185 (14), 109 (100).
Example 3: 5-{3-[3-(4-fluorobenzyloxy)phenyl]propyl}furan-2- carboxylic acid (E)/(Z)-5-{3-[3-(4-fluorobenzyloxy)phenyl]propenyl}furan-2-carboxy lie acid (0.16 mmol) obtained in Example 2 was hydrogenated according to the procedure of Step (1-5) of Example 1, to obtain the title compound (Yield 59%).
1H-NMR (30OMHz5 CDCl3) d 1.93(m, 2H , propyl) , 2.60(m, 4H , propyl), 4.96(s, 2H5 CH2), 6.03 (m, IH5 fur), 6.72-7.39 (m, 9H5 Ph5 fur) MS m/z 354 (M+5 2), 227 (4), 109 (100).
M.P.: 58.7iC ~ 81.l t:
Example 4: 5-(3-{3-[2-(4-fluorophenyl)ethoxy]phenyl}propyl)furan-2- carboxylic acid
2-(4-Fluorophenyl)-ethyl methanesulfonate obtained in Step (1-1) of
Example 1 and 3-hydroxyphenyl acetic acid were used as starting materials for conducting the procedures of Step (1-2) of Example I5 Step (2-3) (Yield 62%) and Step (2-4) (Yield 36%) of Example 2, Step (1-5) of Example 1 and Step (2-5) (Yield 62%) of Example 2, successively, to obtain the title compound.
1H-NMR (300MHz5 CDCl3) d 1.94 (m, 2H5 CH2CH2CH3), 2.61 (t, J= 7.4Hz, 2H, Qi2CH2CH2), 7.21 (t, J= 7.4Hz5 2H5 CH2CH2CH2), 3.05 (t, J = 6.9Hz5 2H5 OCH2CH2), 6.17 (m, IH5 fur), 6.80-7.26 (m, 9H5 fur, Ph); MS m/z 368 (M+, 10O)5 229 (34), 103 (80) M.P.: 131.6°C ~ 132.50C
Example 5: Preparation of 5-{2-[3-(4-fluorobenzyloxy)phenyl]ethyl} furan-2-carboxylic acid
(5-1) Preparation of r3-(4-fluorobenzyloxy)phenyl1methanol
The procedure of Step (2-2) of Example 2 was repeated except for using 3-hydroxybenzyl alcohol as a starting material, to obtain the title compound.
(5-2) Preparation of r3-(4-fluorobenzyloxy)phenyl1iodomethane
Triphenylphosphine (9.52 mmol) was dissolved in 7 mi of dichloromethane, and N-iodosuccinimide (10.0 mmol) was slowly added dropwise thereto. The mixture was stirred for 5 minutes, to which a solution of the compound (3.40 mmol) obtained in Step (5-1) dissolved in dichloromethane (10 m-ft) was slowly added dropwise. After stirring for 3 hours, 5 ml of a saturated sodium hydrogen carbonate (NaHCO3) solution was added to the resulting solution, which was extracted with water and dichloromethane (3:1, 20 ml), and washed with brine. The organic was dried over anhydrous Mg2SO-^ filtered, and concentrated under a reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate = 20: 1), to obtain the title compound (Yield 39 % ).
(5-3) Preparation of (EVf Z)-5- 12- f3-(4-fluorobenzyloxy)phenyll vinyl) furan-2-carboxylic acid
The procedure of Step (1-4) of Example 1 was repeated except for using the compound (0.28 mmol) obtained in Step (5-2), to obtain the title compound (Yield 52%).
(5-4) Preparation of 5-{2-[3-(4-fluorobenzyloxy)phenyllethyl}furan-2- carboxylic acid
The procedure of Step (1-5) of Example 1 was repeated except for using the compound (0.12 mmol) obtained in Step (5-3), to obtain the title compound (Yield 50%).
1H-NMR (300MHz, CDCl3) d 2.97 (m, 4H, CH2CH2), 4.99 (s, 2H, CH2), 6.12 (d, J= 2.7 Hz, IH, fur), 6.78-7.48 (m, 9H, fur, Ph); MS m/z 340 (M+, 2), 123 (22), 109 (100). Example 6: Preparation of 5-{2-[2-(4-fluorobenzyloxy)phenyl] ethyl} furan-2-carboxylic acid
2-Hydroxybenzyl alcohol was used as a starting material for conducting the procedures of Step (2-2) of Example 2 and then Step (1-3) (Yield 62%), Step (1-4) (Yield 34%) and Step (1-5) (Yield 90%) of Example 1, successively, to obtain the title compound.
1H-NMR (300MHz5 CDCl3) d 3.03 (s, 4H, CH2CH2), 5.04 (s, 2H, CH2), 6.05 (m, IH, fur), 6.90-7.40 (m, 9H, Ph, fur) MS m/z 340 (M+, 2), 109 (92), 59(100).
Example 7: Preparation of 5-(2-{2-[2-(4-fluorophenyl)ethoxy]phenyl} ethyl)furan-2-carboxylic acid
2-Hydroxybenzyl alcohol and 2-(4-fluorophenyl)-ethyl methanesulfonate obtained in Step (1-1) of Example 1 were used as starting materials for conducting the procedures of Step (1-2), Step (1-3) (Yield 89%), Step (1-4) (Yield 50%) and Step (1-5) (Yield 90%) of Example 1, successively, to obtain the title compound.
1H-NMR (300MHz, CDCl3) d 2.91 (m, 4H, CH2CH2), 3.08 (t, /= 6.3 Hz, 2H, CH2CH2O), 4.16 (t, J = 6.3 Hz, 2H, CH2CH2O), 6.06 (ά, J = 3.3 Hz, IH, fur), 6.81-7.27 (m, 9H, Ph, fur) MS m/z 354 (M+, 3), 72 (74), 59 (100). M.P.: 58.9°C - 81.10C
Example 8: Preparation of (E/Z)-5-(2-{2-[2-(4-fluorophenyl)ethoxy] phenyl}vinyl)furan~2-carboxylic acid
2-Hydroxybenzyl alcohol and 2-(4-fluorophenyl)-ethyl methane sulfonate obtained in Step (1-1) of Example 1 were used as starting materials for conducting the procedures of Step (1-2), Step (1-3) (Yield 89%) and Step (1-4) (Yield 50%) of Example 1, successively, to obtain the title compound. 1H-NMR (300MHz, CDCl3) d 3.14 (t, J = 6.6 Hz, 2H, CH2CH2O), 4.23 (t, / = 6.6 Hz, 2H, CH2CH2O), 6.43 (d, J = 3.6 Hz, IH, for), 6.86-7.58 (m, HH, CH, fur, Ph) MS m/z 352 (M+, 12), 123 (100), 103 (26). M.P.: 168.4°C ~ 169.0°C .
Example 9: Preparation of (E/Z)-5-{2-[2-(4-fluorobenzyloxy)phenyl] vinyl}furan-2-carboxylic acid
2-Hydroxybenzyl alcohol was used as a starting material for conducting the procedures of Step (2-2) of Example 2, Step (1-3) (Yield 62%) and Step (1-4) (Yield 34%) of Example 1, successively, to obtain the title compound.
1H-NMR (300MHz, CDCl3) d 4.99 (s, 0.9H, CH2), 5.13 (s, 1.1H, CH2), 6.22 (m, 0.45H, for), 6.45 (d, J= 18.9Hz, 0.5H, CH), 6.51 (m, 0.55H, fur), 6.65(d, /= 18.9 Hz, 0.5H, CH), 6.8-7.7 (m, 1OH, Ph, CH, for) MS m/z 338 (M+, 3), 229 (10), 109 (100). M.P.: 80°C ~ 83 °C .
Experimental Example 1 : AMPK activation Test
Hepatoma HepG2 cells obtained from the Korean Cell Line Bank were cultured in DMEM (Dulbecco's Modified Eagle Medium) at a concentration of IxIO4 cells /well. The cells were treated with each of the test compounds of the present invention (100 μM), metformin (2 mM) (Sigma) and AICAR (100 μM) (Sigma) as comparative compounds, and the control group without test compound, which were incubated in a humidified atmosphere of 5% CO2 at 37 °C for 24 hours. Then, the cells were treated with a Pro-Prep protein extract solution (ESTtRON Biotechnology). For Western blotting assay, the extracted protein was separated in SDS-PAGE and electrophoretically transferred to protein-fixing membranes, followed by incubation with the anti-AMPK antibody (Cell signaling) or anti-phospho-AMPK (pAMPK) antibody (Cell signaling). A light-sensitive film was used to detect immunoreactive bands and the intensity of bands was quantified. The AMPK activity increase brought about by the test compound treatment was measured by dividing the intensity of pAMPK with the intensity of AMPK. The results are shown in Table 1, in the form of the extent of increase of the AMPK activity relative to AICAR (The measurement for AICAR is assigned to "1").
Table 1
Figure imgf000019_0001
Experimental Example 2: Effectiveness in inhibiting cholesterol synthesis
The effectiveness in inhibiting cholesterol synthesis of AMPK activated by the inventive compound was evaluated using Hepatoma HepG2 cells according to the following procedure {See Drake M. Amundson and Mingjie Zhou, J Biochem Biophys Methods. Jan 13; 38(l):43-52, 1999).
Hepatoma HepG2 cells obtained from the Korean Cell Line Bank were cultured in DMEM at a concentration of IxIO4 cells /well. The cells were treated with each of the test compounds of the present invention (50 μM), and the control group without test compound, which were incubated in an atmosphere of 5% CO2 at 37 °C for 24 hours. Then, the cells were treated with a cell lysis solution (0.1 M potassium phosphate, pH 7.4, 0.05 M NaCl, 5 inM cholic acid, 0.1% Triton® X-100) and reacted on ice for 10 minutes. The cell lysates were treated with 50 jΛ of a 2 times-concentrated reagent (300 μM Amplex Red reagent (Invitorgen), 2 O/ml HRP (Invitorgen), 2 U/m-β cholesterol oxidase (Invitorgen), 0.2 Wmt cholesterol esterase (Invitorgen)) and reacted for 30 minutes at 37 °C . The content of cholesterol formed in the cell lysates was measured using a fluorscence microscope and .quantified. The results are shown in Table 2, in the form of the cholesterol content (%) relative to the control group (The measurement for control group is assigned to "100%"). Table 2
Figure imgf000020_0001
Experimental Example 3: Effectiveness in inhibiting triglyceride formation
Hepatoma HepG2 cells obtained from the Korean Cell Line Bank were cultured in DMEM at a concentration of 2χl O4 cells /well. The cells were treated with each of the test compounds of the present invention (50 μM), and the control group without test compound, which were incubated in an atmosphere of 5% CO2 at 37 °C for 24 hours. Then, the cells were treated with a cell lysis solution (0.1 M potassium phosphate, pH 7.4, 0.05 M NaCl, 5 mM cholic acid, 0.1% Triton® X-100) and reacted on ice for 10 minutes. The cell lysates were treated with 50 μJL of a 2 times-concentrated reagent (300 μM Amplex Red reagent (Invitorgen), 2 UM lipase (ASAN Pharmaceutical Co., Ltd.), 0.75 UM glycerol kinase (ASAN Pharmaceutical Co., Ltd.), 151333 UM peroxidase (ASAN Pharmaceutical Co., Ltd.), 22.2 UM glyceric oxidase (ASAN Pharmaceutical Co., Ltd.) and reacted for 30 minutes at 37 0C . The content of the triglyceride formed in the cell lysates was measured using a fluorscence microscope and quantified. The results are shown in Table 3, in the form of the triglyceride content (%) relative to the control group (The measurement for control group is assigned to "100%")- Table 3
Figure imgf000021_0001
Experimental Example 4: Effectiveness in inhibiting hepatic gluconeogenesis
Hepatoma HepG2 cells were cultured in DMEM at a concentration of 5χl O4 cells /well. The cells were treated with each of the test compounds of the present invention (50 μM), and the control group without test compound, which were incubated in an atmosphere of 5% CO2 at 370C for 24 hours. Then, 0.5 uCi 14C-lactate (Amersham Bioscience) and 10 mM L-lactate
(Sigma) were treated in the incubation media, and the cells were incubated for 4 hours, followed by removing the media. The cells were washed with PBS, to which 0.1N sodium hydroxide was added and then placed at room temperature for 1 hour. After neutralizing with IN hydrochloric acid, the content of glucose formed in the cells was measured using a liquid scintillation counter (Beckman counter) and quantified. The results are shown in Table 4, in the form of the glucose content (%) relative to the control group (The measurement for control group is assigned to "100%"). Table 4
Figure imgf000022_0001
Experimental Example 5: Effectiveness in muscular glucose utilization C2C12 muscle myoblast cells obtained from the Korean Cell Line Bank were cultured in DMEM containing 10% bovine calf serum. When the cell density was 90%, the culture medium was replaced with DMEM containing 2% bovine calf serum and the cells were cultured for 3 days therein, followed by culturing in the same medium for 2 days, to induce muscle cell differentiation. The cells of 3><105/well were treated with each of the test compounds of the present invention (50 μM), and the control group without test compound, which were then treated with 1 μM insulin (Sigma) and incubated in an atmosphere of 5% CO2 at 37 °C .
Then, 1 uCi 3H-didoxy-glucose (Amersham Bioscience) and 10 μM didoxy-glucose (Sigma) were treated in the incubation media at 37 °C for 15 minutes, followed by removing the media. The cells were washed with PBS, to which 0.1N sodium hydroxide was added. After neutralizing with IN hydrochloric acid, the content of glucose absorbed in the cells was measured using a liquid scintillation counter (Beckman counter) and quantified. The results are shown in Table 5, in the form of glucose content (%) utilized in the muscular cell relative to the control group (The measurement for control group is assigned to "100%"). Table 5
Figure imgf000023_0001
As shown in Tables 1 to 5, the inventive compound is effective in the activation of AMPK, which is useful for preventing or treating metabolic syndromes including diabete (e.g., Type 2 diabete), obesity, hyperlipidemia, hypercholesterolemia, fatty liver and steatohepatitis factors.
While the invention has been described with respect to the specific embodiments, it should be recognized that various modifications and changes may be made by those skilled in the art to the invention which also fall within the scope of the invention as defined as the appended claims.

Claims

What is claimed is:
1. A compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof:
Figure imgf000024_0001
wherein,
X is hydrogen or halogen;
R is hydrogen or Ci-4 alkyl; n is an integer in the range of 1 to 3; and m is an integer in the range of 0 to 2.
2. The compound of claim 1, which is selected from the group consisting of:
1) 5-(2- {3-[2-(4-fluorophenyl)ethoxy]phenyl} ethyl)furan-2~carboxylic acid;
2) (E)/(Z)-5-{3-[3-(4-fluorobenzyloxy)phenyl]propenyl}furan-2-carboxylic acid;
3) 5-{3-[3-(4-fluorobenzyloxy)phenyl]propyl}furan-2-carboxylic acid;
4) 5-(3-{3-[2-(4-fluorophenyl)ethoxy]phenyl}propyl)furan-2-carboxylic acid;
5) 5- {2-[3-(4-fluorobenzyloxy)phenyl]ethyl}furan-2-carboxylic acid;
6) 5-{2-[2-(4-fluorobenzyloxy)phenyl]ethyl}furan-2-carboxylic acid;
7) 5-(2- {2-[2-(4-fluorophenyl)ethoxy]phenyl}ethyl)furan-2-carboxylic acid;
8) (E)/(Z)-5-(2- {2- [2-(4-fluorophenyl)ethoxy]ρhenyl} vinyl)furan-2- carboxylic acid;
9) (E)/(Z)-5-{2-[2-(4-fluorobenzyloxy)phenyl]vinyl}furan-2-carboxylic acid; and a pharmaceutically acceptable salt or isomer thereof.
3. A method for preparing the compound of formula (I) of claim 1, comprising bringing a compound of formula (II) to react with a compound of formula (III) in a solvent in the presence of a base:
Figure imgf000025_0001
wherein,
Y is triphenylphosphonium bromide, triphenylphosphonium iodide or benzothiazol-2-sulfonyl; and
X, R, n and m are the same as defined in claim 1.
4. A pharmaceutical composition for preventing or treating metabolic syndromes, comprising the compound of claim 1, a pharmaceutically acceptable salt or isomer thereof as an active ingredient.
5. The pharmaceutical composition of claim 4, wherein the metabolic syndrome is Type 2 diabete, obesity, hyperlipidemia, hypercholesterolemia, fatty liver or steatohepatitis factors.
PCT/KR2007/003744 2006-08-04 2007-08-03 Furan-2-carboxylic acid derivatives and process for the preparation thereof Ceased WO2008016278A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020060073717A KR100826108B1 (en) 2006-08-04 2006-08-04 Furan-2-carboxylic acid derivative and its manufacturing method
KR10-2006-0073717 2006-08-04

Publications (1)

Publication Number Publication Date
WO2008016278A1 true WO2008016278A1 (en) 2008-02-07

Family

ID=38997413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2007/003744 Ceased WO2008016278A1 (en) 2006-08-04 2007-08-03 Furan-2-carboxylic acid derivatives and process for the preparation thereof

Country Status (2)

Country Link
KR (1) KR100826108B1 (en)
WO (1) WO2008016278A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9192601B2 (en) 2006-12-29 2015-11-24 Salk Institute For Biological Studies Methods for enhancing muscle performance and tone
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051937A2 (en) * 2003-11-21 2005-06-09 Arena Pharmaceuticals, Inc. 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100518184B1 (en) * 2003-12-27 2005-10-04 한국화학연구원 Furancarbonylguanidine derivatives, their preparation and pharmaceutical compositions containing them
KR100633095B1 (en) * 2004-03-20 2006-10-12 한국화학연구원 3,5-position-substituted furan-2-carbonylguanidine derivative, preparation method thereof and pharmaceutical composition comprising the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051937A2 (en) * 2003-11-21 2005-06-09 Arena Pharmaceuticals, Inc. 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OJUKA E.: "Increased expression of GULT-4 and hexokinase in rat epitrochlearis muscle exposed ti AICAR in Vitro", J. APPL. PHYSIOL, vol. 88, no. 3, 2000, pages 1072 - 1075 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9192601B2 (en) 2006-12-29 2015-11-24 Salk Institute For Biological Studies Methods for enhancing muscle performance and tone
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11851429B2 (en) 2020-05-19 2023-12-26 Kallyope, Inc. AMPK activators
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators

Also Published As

Publication number Publication date
KR100826108B1 (en) 2008-04-29
KR20080012621A (en) 2008-02-12

Similar Documents

Publication Publication Date Title
WO2008016278A1 (en) Furan-2-carboxylic acid derivatives and process for the preparation thereof
KR101462393B1 (en) Inhibitors of c-fms kinase
US4711888A (en) Hydroxy and alkoxy pyrimidines
EP0001900B1 (en) 9-thia-12-azaprostanoic acid derivatives and compositions containing them
US7459480B2 (en) Benzodioxepine derivatives
NO874454L (en) NEW DERIVATIVES OF BENZIMIDAZOLES WITH ANTI-ULCUS ACTIVITY AND PROCEDURE FOR THEIR PREPARATION.
US5698567A (en) Heterocyclic spiro compounds
AU2003209679B2 (en) Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPARalpha activation
EP1667988B1 (en) Coumarins as inos inhibitors
US4411899A (en) Substituted derivatives of amino alkane diols as gastric secretion inhibitors
EP1742927B1 (en) Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications threreof
CA1336516C (en) Acyl derivatives of 2-amino-4-substituted-5-hydroxy pyrimidines
US4452986A (en) Imidazolyl-substituted benzofurans
US5051438A (en) Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof, compositions and use
WO2018184561A1 (en) Substituted imidazole salt compounds, preparation method therefor, pharmaceutical composition thereof, and applications thereof
US5021445A (en) Compounds useful for the treatment of hypoglycemia
EP0303348B1 (en) 2-amino-5-hydroxy-4-pyrimidones
EP0259972A2 (en) Heterocyclic propene amide derivatives, processes for their preparation and their use as pharmaceuticals
US5212198A (en) Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof
EP2001846A1 (en) Indole derivatives as inhibitors of the soluble adenylate cyclase
RU2144533C1 (en) Derivatives of tetrazole, method of their synthesis and pharmaceutical compositions based on them
US4910204A (en) 2-amino-5-hydroxy-4-pyrimidones
WO2012061951A1 (en) Method for preparing dronedarone hydrochloride
US4954520A (en) 1,3-dioxolane derivatives useful in the treatment of inflammation
WO2012171135A1 (en) Benzofuran compound, preparation method and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07793381

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07793381

Country of ref document: EP

Kind code of ref document: A1